For pediatric AML, Willier et al. proposed CD33/CLL-1 as the best antigen pairing for “CAR + CCR” approaches, although further in vivo and clinical studies are needed to determine whether targeting these two antigens provides sufficient coverage for AML eradication [143]. Here, CD33 is linked to acute myeloid leukemia.